The goal of this clinical trial is to test the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors) in acute ischemic stroke patients associated with atherosclerosis by investigating
1. the change in lipid profile compared to baseline results 2. the effects on prognosis of stroke The participants will be given PCSK9 inhibitor right after confirmation of acute ischemic stroke, and the investigators will compare the results to the control group, whom are acute ischemic stroke patients treated with conventional lipid lowering therapy, statin and/or ezetimibe.
Non-cardioembolic Stroke
Acute Ischemic stroke within 7 days of symptom onset (confirmed by CT or MRI)
Age 19 and above
Significant stenosis associated with atherosclerosis in major intracranial / extracranial vessels.
Presence of high-risk factors for cardioembolism
Risk of ischemic stroke due to thrombosis from other causes
Patients with hemorrhagic stroke, brain tumors, or brain abscesses
Patients unable to take statins or PCSK9 inhibitors
Sun U. Kwon
Lead sponsor
Asan Medical Center
Sponsor institution